NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading CALC? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making but has shown some improvement in net income and management is focused on advancing clinical development.
The market appears to have low expectations for CALC, as indicated by its low fragility tier. However, the current valuation may not fully reflect the potential upside if management successfully executes on its priorities.
Management is on track to ensure cash sufficiency into Q4 2026 and has shown significant improvement in net income. However, there is a high near-term risk of an earnings miss, given the company's smaller size and erratic earnings history.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. Positive earnings and guidance from these companies could support CALC, while any negative shifts could impact its momentum.
Over the next 1 to 3 years, CALC's prospects depend on management's execution and external sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if net income improvements continue. This impacts investor confidence.
Confirms:Q2 earnings report shows net income above $5 million.
Disproves:Net income falls below $5 million in the Q2 earnings report.
Why it matters: Updates on cash will show financial health. This impacts funding for operations.
Confirms:Management says there will be enough cash through Q4 2026.
Disproves:Management warns of possible cash shortfall before Q4 2026.
Why it matters: FDA feedback will guide the next steps for Auxora's clinical development. This is key for future growth.
Confirms one read:FDA gives good feedback on the program design for Auxora.
Confirms the other:FDA gives bad feedback or delays on the program design.
Why it matters: The earnings report will show how well the company is doing. It will also share plans for the future.
Confirms one read:Announcement of the next earnings date with positive guidance or outlook.
Confirms the other:Announcement of the next earnings date with negative guidance or no updates.
Why it matters: If sector revenue growth rebounds, it could help CalciMedica.
Confirms:Health Care sector revenue growth speeds up to 9% or more.
Disproves:Sector revenue growth keeps slowing below current levels.
Why it matters: The IND submission for CM5480 is a key step for a new treatment for pulmonary hypertension.
Confirms:CalciMedica sends the IND application for CM5480 as planned in mid-2027.
Disproves:The IND submission for CM5480 is delayed or not filed as expected.
